Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14476025 | 0.83 | GRM5 (0.48) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL14358239 | 0.83 | GRM5 (0.48) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL1825269 | 0.83 | GRM5 (0.43) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL852827 | 0.77 | GRM5 (0.51) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL10200739 | 0.74 | HTR2C (0.35) | GRM5 | |
| SCHEMBL22048899 | 0.74 | GRM5 (0.51) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL382392 | 0.74 | GRM5 (0.51) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL26457526 | 0.73 | ALDH1A1 (0.40) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL18237835 | 0.73 | GRM5 (0.48) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL12329716 | 0.72 | MBOAT4 (0.46) | GRM5ALDH1A1GAAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| EP-3689860-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2019063015-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS RORγ INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | RORC, RORA, RORB | GRM5 509/4885ALDH1A1 902/4885GAA 2473/4885 |
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | RORC, RORA, RORB | GRM5 509/4885ALDH1A1 902/4885GAA 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.